We are developing
A single platform for defeating cancer and much more.
We are HEPHAISTOS-Pharma
A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.
One need, one mission :
Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.
Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.
Team
International experts & experimented operational team
Advisory Board
Pr. Charles Dumontet,
Deputy Director CRCL Physician in Hematology. Oncology KOL.
Pr. of Hematology in University of Lyon Deputy Director CRCL. President of the Clinical Research and Innovation Department and also Vice-President of Research at HCL
Pr. Jean-Yves Blay,
General Director at the Centre Léon Bérard, Oncology KOL.
President of the French Federation of Cancer Centers Unicancer, coordinator of European Reference Network on rare adult cancers, EURACAN
Dr. Nathalie Garçon, CEO and CSO BIOASTER, Adjuvant KOL
PharmD. PhD. Former Vice President, Head of the Adjuvant and Technology Innovation Center at GSK Vaccines, 2014 Stanley Plotkin Award for lifetime achievement in vaccines
Dr. Olivier Favre-Bulle,
CEO at 3BIOTECH Consulting, CMC Expert
Chemical Engineer, Bio-engineering PhD, MBA, Former Project manager at Sanofi, Covanc, Novo Nordisk, CMC Consultant.
Market Needs
Turning cold tumors into hot tumors
Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy
Innovation & advantages
Onco-Boost platform
ONCO-Boost is the Fisrt-In-Class Immunostimulant injectable intravenous able to treat metastatic and hardly accessible cancer like Osteorcoma
Mechanism of Action
Mechanism of Action (MoA)
ONCO-Boost
will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.
Monoclonal
Antibody (mAb)
will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.
All together
By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.
Publications
Pipeline
News
Come in we’re hiring
HEPHAISTOS is currently hiring a Preclinical Development Manager,…
Media coverage
02 November 2020
Clusters & Partners
Supports
HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund
HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.
HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937
HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.